RAPT Therapeutics(RAPT) - 2024 Q1 - Quarterly Results

Exhibit 99.1 RAPT Therapeutics Reports First Quarter 2024 Financial Results Company maintains solid cash position of $141.6 million SOUTH SAN FRANCISCO, Calif. – May 9, 2024 – RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today reported financial results for the first quarter ended March 31, 202 ...